Market research
603658.SHG Autobio Diagnostics Co., Ltd
SHG CNY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 20B
- P/E ratio
- 20.38
- Analyst target
- 38.1875
- Dividend yield
- 3.8%
- Beta
- 0.0
Profile
Instrument facts
- Exchange
- SHG
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- CNE100002GC4
- Market cap
- 20B
- P/E ratio
- 20.38
- Analyst target
- 38.1875
- Dividend yield
- 3.8%
- Beta
- 0.0
About
About Autobio Diagnostics Co., Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an automatic immunoassay analyzer; AutoLumo A2000 Plus, an automated chemiluminescence immunoassay analyzer; PHOmo microplate readers; LUmo microplate luminometers; and iWO-960 microplate washers. The company's microbiology products include AutoMic-I60 for microbial identification and antibiotic susceptibility testing; AutoStreak S1800, a microbial sample pretreatment system; Autof T series and MALDI-TOF MS system for the identification of pathogenic bacteria; AutoMimo 1200, an instrument for improving pipetting efficiency and optimize workflow in the lab; BC60, an automatic blood culture instrument; and BC120, an automated bacterial culturing and detection. It also provides blood culture bottles and mycoplasma TIES reagents; AutoMolec 1600, an integrated and automated molecular diagnostics analyzer; AutoMolec 3000, an in vitro molecular detection instrument; Ci-120x and Ci-310 benchtop coagulation analyzers; and Autolas Bi 1000, Autolas Bi2600, AutoChem B861, and AutoChem B2000 automated biochemistry analyzers, as well as Autolas X series, and Autolas B series. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is headquartered in Zhengzhou, China. Autobio Diagnostics Co., Ltd. is a subsidiary of Zhengzhou Autobio Co., Ltd.
Research context
Autobio Diagnostics Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 603658.SHG discussion.
5 years, 6 months ago
Autobio Diagnostics Co., Ltd is currently in a long term downtrend where the price is trading 27.1% below its 200 day moving average.
From a valuation standpoint, the stock is 73.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16.7.
Autobio Diagnostics Co., Ltd's total revenue rose by 17.8% to $842M since the same quarter in the previous year.
Its net income has increased by 10.4% to $240M since the same quarter in the previous year.
Finally, its free cash flow fell by 322.2% to $-209M since the same quarter in the previous year.
Based on the above factors, Autobio Diagnostics Co., Ltd gets an overall score of 2/5.